(UroToday.com) 12 core systematic prostate biopsy is the standard of care in the diagnosis of prostate cancer and has been for decades. It has a low sensitivity and specificity in detecting clinically significant cancer. They may only sample 0.04% of the gland,1 and it has difficulty reaching the anterior and apical regions of the prostate,2 while it is less effective in patients with prior negative biopsy. Physicians are, in fact, blind to the tumor locations when performing only a 12-core systematic prostate biopsy.